Groundbreaking Biomedical Innovation: AmeboGenesis Unveils Eco-friendly Amebocyte Production for LAL Tests

AmeboGenesis™ has announced a major achievement in biomedical testing with the development of a sustainable amebocyte production method. This technology is poised to eliminate the need for bleeding approximately 800,000 horseshoe crabs annually, a practice which is critical for the production of Limulus Amebocyte Lysate (LAL) used worldwide in medical endotoxin testing. Traditional LAL production methods have raised concerns about the survival of horseshoe crabs, potentially pushing them towards endangerment.

The proprietary technology by AmeboGenesis enables limitless production of bio-identical amebocytes, meeting LAL testing's strict standards while mitigating environmental impacts. This novel method ensures reliable, reproducible LAL sources by culturing and differentiating amebocytes from horseshoe crab leg muscle tissues using totipotent stem cells. It not only promises consistent LAL concentration and production but also precision in laboratory settings, enhancing test reliability, accuracy, and robustness.

This breakthrough by AmeboGenesis signifies the first instance of expanding and differentiating amebocyte precursors in cell cultures, producing cells with genetic, morphological, biochemical, and functional similarities to their native counterparts. These cultured cells have been validated for endotoxin response efficacy, setting a new industry standard.